Telomere Therapeutics — Seed · €1.89M

CDTI, through its Innvierte programme, invested €890K alongside Invivo Ventures (€1M), for €1.89M in total. The money was to select the lead AAV-telomerase candidate for idiopathic pulmonary fibrosis and move it towards human trials. Invivo's €1M may be part of its €1.5M commitment announced in December 2020. No lead was named. From 2022 the company also received more than €3M in non-dilutive Spanish grants (RETOS CPP, CDTI NEOTEC). In November 2025 it was reported to be preparing a new round, with no close reported so far.